Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses advances and challenges in the treatment of acute myeloid leukemia (AML), with the approval of several targeted therapies including gilteritinib and midostaurin, IDH inhibitors including ivosidenib, venetoclax, a BCL-2 inhibitor approved in combination with azacitidine, as well as immune therapies such as gemtuzumab ozogamicin. Dr Daver also discusses minimal residual disease (MRD) directed therapies as an unmet need in AML treatment and management and highlights MRD positivity as a marker for inferior response and outlines immune agents as a promising approach to ameliorate this. Lastly, Dr Daver highlights TP53 mutant AML and therapies in development for AML patients with this mutational profile, including APR/venetoclax combination therapies as well as cusatuzumab which has shown efficacy in TP53 adverse AML patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть